Cassar Olivier, Gessain Antoine
Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, Institut Pasteur, 28 rue du Dr. Roux, F-75015, Paris, France.
CNRS, UMR 3569, 28 rue du Dr. Roux, F-75015, Paris, France.
Methods Mol Biol. 2017;1582:3-24. doi: 10.1007/978-1-4939-6872-5_1.
We estimated that at least 5-10 million individuals are infected with HTLV-1. Importantly, this number is based on the study of nearly 1.5 billion people living in known human T-cell lymphotropic virus type 1 (HTLV-1) endemic areas, for which reliable epidemiological data are available. However, for some highly populated regions including India, the Maghreb, East Africa, and some regions of China, no consistent data are yet available which prevents a more accurate estimation. Thus, the number of HTLV-1 infected people in the world is probably much higher. The prevalence of HTLV-1 prevalence varies depending on age, sex, and economic level in most HTLV-1 endemic areas. HTLV-1 seroprevalence gradually increases with age, especially in women. HTLV-1 has a simian origin and was originally acquired by humans through interspecies transmission from STLV-1 infected monkeys in the Old World. Three main modes of HTLV-1 transmission have been described; (1) from mother-to-child after prolonged breast-feeding lasting more than six months, (2) through sexual intercourse, which mainly, but not exclusively, occurs from male to female and lastly, (3) from contaminated blood products, which contain HTLV-1 infected lymphocytes. In specific areas, such as Central Africa, zoonotic transmission from STLV-1 infected monkeys to humans is still ongoing.The diagnostic methods used to study the epidemiological aspects of HTLV-1 infection mainly consist of serological assays for the detection of antibodies specifically directed against different HTLV-1 antigens. Screening tests are usually based on enzyme-linked immunoabsorbent assay (ELISA), chemiluminescence enzyme-linked immunoassay (CLEIA) or particle agglutination (PA). Confirmatory tests include mostly Western blots (WB)s or innogenetics line immunoassay (INNO-LIA™) and to a lesser extent immunofluorescence assay (IFA). The search for integrated provirus in the DNA from peripheral blood cells can be performed by qualitative and/or quantitative polymerase chain reaction (qPCR). qPCR is widely used in most diagnostic laboratories and quantification of proviral DNA is useful for the diagnosis and follow-up of HTLV-1 associated diseases such as adult T-cell leukemia (ATL) and tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM). PCR also provides amplicons for further sequence analysis to determine the HTLV-1 genotype present in the infected person. The use of new generation sequencing methodologies to molecularly characterize full and/or partial HTLV-1 genomic regions is increasing. HTLV-1 genotyping generates valuable molecular epidemiological data to better understand the evolutionary history of this virus.
我们估计,至少有500万至1000万人感染了人类嗜T淋巴细胞病毒1型(HTLV-1)。重要的是,这一数字是基于对生活在已知人类嗜T淋巴细胞病毒1型(HTLV-1)流行地区的近15亿人进行的研究得出的,这些地区有可靠的流行病学数据。然而,对于一些人口密集的地区,包括印度、马格里布、东非和中国的一些地区,尚无一致的数据,这妨碍了更准确的估计。因此,全球HTLV-1感染人数可能要高得多。在大多数HTLV-1流行地区,HTLV-1的流行率因年龄、性别和经济水平而异。HTLV-1血清阳性率随年龄逐渐增加,尤其是在女性中。HTLV-1起源于猿类,最初是人类通过旧世界中感染了猴嗜T淋巴细胞病毒1型(STLV-1)的猴子进行种间传播而获得的。已描述了HTLV-1传播的三种主要方式:(1)长期母乳喂养超过六个月后母婴传播;(2)通过性行为传播,主要但不限于男性向女性传播;最后,(3)通过含有感染HTLV-1淋巴细胞的受污染血液制品传播。在特定地区,如中非,从感染STLV-1的猴子到人畜共患病传播仍在继续。用于研究HTLV-1感染流行病学方面的诊断方法主要包括血清学检测,以检测针对不同HTLV-1抗原的特异性抗体。筛查试验通常基于酶联免疫吸附测定(ELISA)、化学发光酶联免疫测定(CLEIA)或颗粒凝集试验(PA)。确证试验主要包括免疫印迹法(WB)或Innogenetics线性免疫测定(INNO-LIA™),较少使用免疫荧光测定(IFA)。可通过定性和/或定量聚合酶链反应(qPCR)在外周血细胞DNA中搜索整合前病毒。qPCR在大多数诊断实验室中广泛使用,前病毒DNA定量对诊断和随访HTLV-1相关疾病如成人T细胞白血病(ATL)和热带痉挛性截瘫/HTLV-1相关脊髓病(TSP/HAM)很有用。PCR还提供扩增子用于进一步的序列分析,以确定感染者中存在的HTLV-1基因型。使用新一代测序方法对HTLV-1基因组的全部和/或部分区域进行分子特征分析的情况正在增加。HTLV-1基因分型产生有价值的分子流行病学数据,以更好地了解这种病毒的进化史。